

ASX RELEASE

Volpara proudly attains B Corp Certification

Highlights:

- **B Corp Certification measures companies' total social and environmental impact**
- **Certification is conducted by B Lab, a non-profit network dedicated to transforming the global economy**
- **As a Certified B Corp, Volpara joins over 4,600 companies that meet B Lab's high standards of performance, accountability, and transparency**

Wellington, NZ, 11 October 2022: Volpara Health Technologies ("Volpara," "the Group," or "the Company"; ASX:VHT), a global leader in software for the early detection and prevention of breast cancer, today announced that it is a Certified B Corporation, or B Corp.

Certified B Corporations represent a growing for-profit business community that puts people and the planet first. Companies that become B Corp certified lead in their ability to meet high standards for social and environmental performance. By achieving a score of 80 or higher on the B Impact Assessment, incorporating stakeholder governance in their legal structure, and undergoing review and recertification every three years, B Corps commit to continuous improvement.

As a purpose-driven company focused on saving families from cancer, Volpara is guided by our core values to be bold, relentless, extraordinary, and whānau (the Māori concept of extended family). B Corp Certification reinforces what's long been part of the Company's DNA: to do right by everyone impacted by our decisions and actions from employees and customers to business partners and investors, and of course the individuals whose lives we hope to better, even save, with science. Since our inception we have held ourselves accountable for not only doing the noble work of early cancer detection but participating in the world as a good corporate citizen.

"After over a decade of game-changing innovation in healthcare, it was clear to us that our next step was B Corp Certification," said Volpara Chief People Officer Kathryn Greene. "We are proud to be one of the first companies in our industry that have pursued this extensive certification—a lengthy process that involved hard work from many on our team passionate about corporate stewardship."

Volpara joins a community of over 4,600 other B Corps spanning more than 150 industries in countries around the world, including Australia, New Zealand, and the United States. B Corp-certified companies play a key role in positively impacting and transforming the global economy into a more inclusive, equitable, and regenerative system.

Volpara's strategy includes four pillars: improving cancer detection, building a principled and resilient business, supporting a thriving workforce of dedicated staff members, and practicing responsible climate stewardship. Backed by the growing network of B Corps, Volpara is excited to continue working toward this mission and demonstrating its commitment to the planet.

"We are proud to join this collective effort to make a larger, positive impact together," said Volpara CEO Teri Thomas. "We take our responsibility to our local and global communities very seriously and, like B Lab, believe that profitable growth goes hand in hand with an expanded commitment to transformative social and environmental change."

Authorisation & Additional Information

This announcement was authorised by the CEO of Volpara Health Technologies Limited.

ENDS

For further information, please contact:

Teri Thomas, CEO
Volpara Health Technologies
teri.thomas@volparahealth.com
t: +64 4 499 6029

Hannah Howlett
WE Communications
WE-AUVolpara@we-worldwide.com
t: +61 407 933 437

About Volpara Health Technologies Limited (ASX:VHT)

Volpara Health Technologies makes software to save families from cancer. Healthcare providers use Volpara to better understand cancer risk, empower patients in personal care decisions, and guide recommendations about additional imaging, genetic testing, and other interventions. Our AI-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality, positioning, compression, and dose. In an industry facing increasing staffing shortages, our software streamlines operations and provides key performance insights that support continuous quality improvement.

Volpara is the preferred partner of leading healthcare institutions around the world. Our software is used in over 2,000 facilities by more than 5,000 technologists, impacting nearly 16 million patients globally. It helps providers conduct more than three million cancer risk assessments each year and can be deployed stand-alone or fully integrated with electronic health record systems, mammography reporting systems, imaging hardware, and genetic laboratories. Volpara holds the most rigorous security certifications and numerous patents and regulatory registrations, including FDA clearance and CE marking. Since listing on the ASX in April 2016, the Company has raised A\$132 million. With offices in Seattle and Boston, Volpara is based in Wellington, New Zealand.

For more information, visit www.volparahealth.com